VRDN
Viridian Therapeutics Inc

9,437
Mkt Cap
$2.9B
Volume
853,062.00
52W High
$34.29
52W Low
$9.90
PE Ratio
-7.44
VRDN Fundamentals
Price
$29.85
Prev Close
$28.34
Open
$28.60
50D MA
$30.81
Beta
1.08
Avg. Volume
1.44M
EPS (Annual)
-$3.32
P/B
4.89
Rev/Employee
$281,146.83
$1,947.18
Loading...
Loading...
News
all
press releases
Viridian Therapeutics (NASDAQ:VRDN) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded shares of Viridian Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Propel Bio Management LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN
Propel Bio Management LLC acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the third quarter, according to its most recent filing with the Securities and...
MarketBeat·4d ago
News Placeholder
Viridian Therapeutics, Inc. $VRDN Position Increased by Fisher Asset Management LLC
Fisher Asset Management LLC lifted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 135.6% during the 3rd quarter, according to the company in its most recent disclosure...
MarketBeat·5d ago
News Placeholder
Royal Bank Of Canada Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price
Royal Bank Of Canada decreased their target price on shares of Viridian Therapeutics from $45.00 to $42.00 and set an "outperform" rating for the company in a research report on Friday...
MarketBeat·10d ago
News Placeholder
Viridian Therapeutics (NASDAQ:VRDN) Releases Earnings Results, Misses Expectations By $0.18 EPS
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus...
MarketBeat·11d ago
News Placeholder
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of -20.67% and -99.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today...
Business Wire·11d ago
News Placeholder
MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates
MiMedx (MDXG) delivered earnings and revenue surprises of +55.56% and +14.93%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
Key PointsCommodore Capital exited 3,200,000 shares of Viridian Therapeutics...
Nasdaq News: Markets·14d ago
News Placeholder
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages
Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the fifteen research firms that are currently covering the company...
MarketBeat·20d ago
<
1
2
...
>

Latest VRDN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.